2015 American Transplant Congress
Influence of CYP3A5 and ABCB1 Genotypes on Pharmacokinetics of Immediate and Prolonged Release Tacrolimus Preparations
Background. Tacrolimus is available in two formulations, immediate-release, (Prograf®) and prolonged -release formulation of tacrolimus (Advagraf®). Tacrolimus has a narrow therapeutic index with wide variation…2015 American Transplant Congress
Once Daily Dosing Is as Effective as Twice Daily Dosing of Immediate Release Tacrolimus
1Barnes-Jewish Hospital, St. Louis; 2Washington University School of Medicine, St. Louis.
Purpose: Extended release (ER) tacrolimus (tac) has been available as Advagraf® for many years and as Astagraf XL® in the US since 2013. Immediate release…2015 American Transplant Congress
Pharmacokinetics of Everolimus (EVL) in Elderly Recipients Under Low-Tacrolimus(TAC)/Everolimus in the First Year After Renal Transplantation. Data from the NEverOLd Trial
Elderly ( >60 years) recipients are being renal transplanted more frequently. The pharmacokinetics studies (PK) of immunosuppressive drugs in healthy volunteers, rarely, if ever, include…2015 American Transplant Congress
Treatment With Everolimus and Reduced-Exposure Cyclosporine Is Efficacious in De Novo Renal Transplant Recipients at Increased Risk for Efficacy Failure: Post-Hoc Analysis from the A2309 Study
1For the A2309 Study Group, Italy; 2Novartis, Basel, Switzerland.
Purpose: Data is limited on the effect of everolimus (EVR) based regimens in renal transplant recipients (RTxR) who are at increased risk for rejection and…2015 American Transplant Congress
Factors Affecting Efficacy Outcomes at 12 and 24-Months After Kidney Transplantation in Patients from the A2309 Study
1Novartis, Basel, Switzerland; 2A2309 Study Group, Basel, Switzerland; 3Novartis, East Hanover, NJ.
Purpose: Efficacy outcomes post-transplantation are influenced by donor and recipient variables and interactions between them. Here, we present data from a multivariate analysis of risk…2015 American Transplant Congress
Everolimus Plus Reduced-Exposure Calcineurin Inhibitor Versus Mycophenolate Mofetil Plus Standard-Exposure Calcineurin Inhibitor: 2-Year Results in Living Donor Kidney Transplant Recipients
Purpose: To evaluate the long-term efficacy and safety of everolimus (EVR) plus reduced cyclosporine (rCsA) compared to mycophenolate mofetil (MMF) plus standard cyclosporine at 24…2015 American Transplant Congress
Increasing Tacrolimus Exposure to Minumize Chronic Rejection: How Can We Do It? What Are the Risks?
Background: Recent studies suggest that increased tacrolimus (TAC) exposure may help prevent production of donor specific HLA antibodies (DSAs) that mediate chronic rejection of renal…2015 American Transplant Congress
"What's the Mileage?" Determining the Length of Time in Which Renal Function Returns to Pre-Calcineurin Discontinuation Levels in Patients With Interstitial Fibrosis
The Ohio State University, Columbus.
Calcineurin Inhibitors (CNI) use may be associated with progressive renal dysfunction. Clinical trials have shown that CNI minimization or discontinuation may aid in improvement in…2015 American Transplant Congress
Superior Renal Function in an Everolimus-Based Calcineurin Inhibitor Free Regimen Compared to Standard Cyclosporine/Mycophenolate and Low Cyclosporine/Everolimus: Follow-Up of the HERAKLES Study at Month 48
1Herakles Study Group, Germany; 2Novartis, Pharma, Germany; 3Herakles Study Group, Switzerland.
Aim: To follow up on renal function (GFR) at month (Mo) 48 after kidney transplantation (Tx) in patients (pts) on immunosuppressive regimen with different calcineurin…2015 American Transplant Congress
NFAT Regulated Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Recipients
Purpose of Study:To demonstrate that profiling kidney transplant recipients (KTR) on Tacrolimus (Tac) based immunosuppression based on quantitative analysis of NFAT (nuclear factor of activated…
American Transplant Congress abstracts